海翔药业
(002099)
| 流通市值：85.21亿 | | | 总市值：85.31亿 |
| 流通股本：16.17亿 | | | 总股本：16.19亿 |
| 利润表 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 营业总收入 | 486,496,687.33 | 1,860,693,572.54 | 1,366,585,897.97 | 925,159,120.06 |
| 营业总成本 | 494,767,487.53 | 1,897,235,398.52 | 1,336,577,933.58 | 892,850,523.47 |
| 其他经营收益 | | | | |
| 营业利润 | 25,459,221.62 | -80,025,705.83 | 24,138,438.48 | 24,780,775.8 |
| 利润总额 | 26,113,433.19 | -84,091,024.28 | 18,583,995.86 | 19,295,294.1 |
| 净利润 | 26,302,843.26 | -93,754,370.28 | 5,037,099.22 | 12,623,205.93 |
| 每股收益 | | | | |
| 其他综合收益 | - | 14,373,444.92 | - | - |
| 综合收益总额 | 26,302,843.26 | -79,380,925.36 | 5,037,099.22 | 12,623,205.93 |
| 资产负债表 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 流动资产: | | | | |
| 流动资产合计 | 2,429,852,996.23 | 2,832,616,084.92 | 2,879,736,795.87 | 3,240,546,292.58 |
| 非流动资产: | | | | |
| 非流动资产合计 | 4,616,784,633.52 | 4,500,487,702.63 | 4,397,907,673.06 | 4,432,396,876.13 |
| 资产总计 | 7,046,637,629.75 | 7,333,103,787.55 | 7,277,644,468.93 | 7,672,943,168.71 |
| 流动负债: | | | | |
| 流动负债合计 | 2,022,555,098.35 | 2,215,778,753.85 | 2,079,923,896.88 | 2,438,213,104.56 |
| 非流动负债: | | | | |
| 非流动负债合计 | 92,040,867.53 | 86,526,913.01 | 86,946,519.07 | 90,276,334.85 |
| 负债合计 | 2,114,595,965.88 | 2,302,305,666.86 | 2,166,870,415.95 | 2,528,489,439.41 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 4,940,991,071.15 | 5,039,603,956.64 | 5,120,268,453.59 | 5,153,165,463.63 |
| 股东权益合计 | 4,932,041,663.87 | 5,030,798,120.69 | 5,110,774,052.98 | 5,144,453,729.3 |
| 负债和股东权益合计 | 7,046,637,629.75 | 7,333,103,787.55 | 7,277,644,468.93 | 7,672,943,168.71 |
| 现金流量表 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 410,139,995.24 | 1,590,168,231.45 | 1,227,789,123.52 | 864,300,595.69 |
| 经营活动现金流出小计 | 463,105,503.52 | 1,649,846,600 | 1,210,831,537.63 | 863,038,479.89 |
| 经营活动产生的现金流量净额 | -52,965,508.28 | -59,678,368.55 | 16,957,585.89 | 1,262,115.8 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 11,702,045.46 | 464,786,527.29 | 426,848,107.24 | 411,730,729.06 |
| 投资活动现金流出小计 | 146,304,821.23 | 157,158,470.85 | 373,160,893.47 | 354,672,262.04 |
| 投资活动产生的现金流量净额 | -134,602,775.77 | 307,628,056.44 | 53,687,213.77 | 57,058,467.02 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 263,706,000 | 2,699,830,000 | 1,982,670,000 | 1,461,500,000 |
| 筹资活动现金流出小计 | 574,058,594.32 | 2,596,806,364.58 | 1,937,260,773.11 | 1,072,270,504 |
| 筹资活动产生的现金流量净额 | -310,352,594.32 | 103,023,635.42 | 45,409,226.89 | 389,229,496 |
| 汇率变动对现金及现金等价物的影响 | -17,351,551.77 | -29,127,288.64 | -5,527,511.7 | 3,156,614.34 |
| 现金及现金等价物净增加额 | -515,272,430.14 | 321,846,034.67 | 110,526,514.85 | 450,706,693.16 |
| 期末现金及现金等价物余额 | 742,701,921.95 | 1,257,974,352.09 | 1,046,654,832.27 | 1,386,835,010.58 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | 321,846,034.67 | - | 450,706,693.16 |